KARD ▲ +14.1% - Kardigan, Inc.
$KARD Kardigan Completes Enrollment in Phase 2b KATALYST-AV Trial and Announces New Evidence Supporting Patient Selection and Endpoints for the Evaluation of Ataciguat in Aortic Stenosis
06-NOV-2026 04:05 PM ET
Share this post
More filings for $KARD
KARD ▲ +0.2% - Kardigan, Inc.Oct 22, 2026KARD - Kardigan, Inc. - SEC Filing Update (01-OCT-2026) | ThinkSabio - Stocks SimplifiedOct 1, 2026KARD - Kardigan, Inc. - SEC Filing Update (13-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 13, 2026KARD - Kardigan, Inc. - SEC Filing Update (13-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 13, 2026KARD - Kardigan, Inc. - SEC Filing Update (07-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 7, 2026KARD - Kardigan, Inc. - SEC Filing Update (06-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 6, 2026
View full $KARD filing history →💬 Comments
Loading comments…
Leave a comment